Novo Nordisk Rebrands to Novo, Targets Eli Lilly — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Novo Nordisk is rebranding to "Novo" — though "Novo Nordisk" remains the legal name, which originated in a 1989 merger of two Danish pharma companies — calling the change "the beginning of a new chapter."
- CEO Mike Doustdar told CNBC the rebrand and culture shift are "part of the same package" to win back customers from Eli Lilly, with fuller strategy details due at a Capital Markets Day on Sept. 21.
- Novo announced four new cultural tenets: patient-focused innovation, greater value for stakeholders, clearer priorities with simpler workflows, and no compromise on patient safety and ethics.
- Novo's shares are down roughly 15% year-to-date even as oral Wegovy cleared 3 million prescriptions by June and beat rival Lilly's weight-loss pill Foundayo to market.
- Novo scrapped three trials of an experimental cardiovascular drug and holds just 38.8% of the obesity market versus Eli Lilly's 60.9% in Q2, according to IQVIA data cited in Lilly's earnings presentation.
- The new marketing campaign, "Lasting Health Starts Now," is positioned to rebuild public trust and relevance as more of Novo's products shift to direct-to-consumer distribution.
Why it matters: Novo's roughly 15% year-to-date stock decline sits alongside a brutal market share gap — 38.8% to Lilly's 60.9% in Q2 obesity sales per IQVIA — forcing a rebrand, cultural overhaul, and a Sept. 21 Capital Markets Day where investors will demand a credible path back to growth. The pivot matters concretely for shareholders, who need to see Novo convert oral Wegovy's 3 million-plus prescriptions into actual share gains against Lilly.
Ask SkimNews
